E. S. Drachuk, A. A. Gubanova, I. Haidbayev, V. N. Burmistrova, K. A. Andreyanova, Yu. A. Hertek, V. E. Tuchina, S. V. Kuzmina, O. V. Kulikova, A. R. Borodina, A. A. Petrakov, S. M. Om, V, V. Babyuk
{"title":"Efficacy of the drug maribavir according to clinical studies","authors":"E. S. Drachuk, A. A. Gubanova, I. Haidbayev, V. N. Burmistrova, K. A. Andreyanova, Yu. A. Hertek, V. E. Tuchina, S. V. Kuzmina, O. V. Kulikova, A. R. Borodina, A. A. Petrakov, S. M. Om, V, V. Babyuk","doi":"10.30629/0023-2149-2024-102-2-101-108","DOIUrl":null,"url":null,"abstract":" Modern medicine has a high demand for new drugs for the prevention and treatment of cytomegalovirus (CMV) infection. This review discusses maribavir — an oral antiviral drug with selective multimodal anti-CMV activity for the treatment of adults and children with post-transplant CMV infection resistant to traditional anti-CMV therapy. Despite numerous clinical trials of maribavir, the results of its effi cacy are ambiguous. Alongside successful studies indicating high effi cacy of the drug under review, there are data from statistically unsuccessful studies. The aim of this review is to examine the mechanism of its action on cytomegalovirus infection, viral sensitivity and cross-resistance mechanisms, as well as to summarize the results of clinical trials of the drug.","PeriodicalId":10439,"journal":{"name":"Clinical Medicine (Russian Journal)","volume":"49 S246","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine (Russian Journal)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30629/0023-2149-2024-102-2-101-108","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Modern medicine has a high demand for new drugs for the prevention and treatment of cytomegalovirus (CMV) infection. This review discusses maribavir — an oral antiviral drug with selective multimodal anti-CMV activity for the treatment of adults and children with post-transplant CMV infection resistant to traditional anti-CMV therapy. Despite numerous clinical trials of maribavir, the results of its effi cacy are ambiguous. Alongside successful studies indicating high effi cacy of the drug under review, there are data from statistically unsuccessful studies. The aim of this review is to examine the mechanism of its action on cytomegalovirus infection, viral sensitivity and cross-resistance mechanisms, as well as to summarize the results of clinical trials of the drug.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
